A Chinese patent covering methods and compositions for the use of CRISPR-Cas9 in eukaryotes has been granted to Dublin-based Ers Genomics Ltd., making what Michael Arciero, vice president of intellectual property and commercial development at the company, called “a strong but not surprising statement by China,” which has made the biotechnology industry one of its top national priorities.